All Stories

  1. Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to M. tuberculosis infection
  2. Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6
  3. Genetic and geographic influence on phenotypic variation in European sarcoidosis patients
  4. Prevention of M2 polarization and temporal limitation of differentiation in monocytes by extracellular ATP
  5. Response
  6. Analysis of single nucleotide polymorphisms in chronic beryllium disease
  7. Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer
  8. A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust
  9. Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease
  10. Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis
  11. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) – protocol for a multi-center, single-arm phase IIa trial
  12. Vasoactive Intestinal Peptide in Checkpoint Inhibitor–Induced Pneumonitis
  13. Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30
  14. The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals
  15. Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients
  16. Bronchoalveolar lavage in healthy and diseased individuals
  17. Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis
  18. Correction: Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?
  19. Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota
  20. Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?
  21. P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis
  22. Sarcoidosis: Drugs under Investigation
  23. The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease
  24. Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis
  25. Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis
  26. Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations
  27. Sarcoidosis: Pathogenesis and Epidemiology . . . . . . . . . . . . . Gernot Zissel, Antje Prasse, and Joachim M€uller-Quernheim
  28. Neue pathogenetische Konzepte und frühe pharmakologische Studien bei der Sarkoidose
  29. Specific antigen(s) in sarcoidosis: a link to autoimmunity?
  30. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer
  31. Chronische Berylliose
  32. Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis
  33. Genetik der Sarkoidose
  34. Are bronchoalveolar lavages a good source for microbial profiling? Differences between throat and bronchoalveolar lavage microbiomes
  35. Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  36. The chemokine CCL18 characterises Pseudomonas infections in cystic fibrosis lung disease
  37. Cellular Activation in the Immune Response of Sarcoidosis
  38. mRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients
  39. Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation
  40. Genetisches Risikoprofil der Sarkoidose
  41. Sarcoidosis
  42. Sarcoidosis
  43. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis
  44. CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Elevates the Invasive Potential
  45. Genetics
  46. Effect of CCL18 on Epithelial-Mesenchymal Transition (EMT) of alveolar epithelial cells
  47. Influence of Phosphodiesterase-Inhibitor PDE4 Roflumilast N-Oxide on Surfactant Protein of human Alveolar Epithelial Cell Type II
  48. CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Enhances Metastatic Potential
  49. Chemotaxis and Transcription Factor Activation of Wild-Type and CCR6-Transfected RLE-6TN
  50. Alternative screening assay to beryllium lymphocyte proliferation test for identification of beryllium sensitization – Pilot study
  51. Differenzial analysis of antioxidative capacities in the alveolar compartment of diffuse parenchymal lung disorders and diseased controls
  52. Characterization of the lung microbiome in sarcoidosis and healthy individuals with respect to host genotype
  53. A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1
  54. Genome-wide association analysis reveals 12q13.3–q14.1 as new risk locus for sarcoidosis
  55. Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas
  56. Roflumilast-N-oxide Induces Surfactant Protein Expression in Human Alveolar Epithelial Cells Type II
  57. Pathogenesis of sarcoidosis
  58. CCL18 -- Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis
  59. Serum Level Of CC-Chemokine Ligand 18 Is Increased In Patients With Non Small Cell Lung Cancer And Correlates With Survival Time In Adenocarcinoma
  60. Differential Cell Counts Of Bronchoalveolar Lavage In 250 Healthy Volunteers
  61. Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages Is Modulated by Interferons In Vitro
  62. Autorinnen und Autoren
  63. Die Serumkonzentration des CC Chemokin ligand 18 (CCL18) ist bei Patienten mit NCCLC erhöht und korreliert mit der Überlebenszeit
  64. CC Chemokin ligand 18 (CCL18) induziert Chemotaxis, EMT und Chemo-Resistance bei der Lungenkarzinomzelllinie A549
  65. Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung
  66. Purinergic Receptor Type 6 Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation
  67. Identification Of The CCL18 Receptor - Effects Of CCL18 On Human Lung Fibroblasts In Pulmonary Fibrosis Are Mediated Via CCR6
  68. P2X7Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema
  69. Alternatively activated alveolar macrophages in pulmonary fibrosis—mediator production and intracellular signal transduction
  70. Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis
  71. Immunologic Response of Sarcoidosis
  72. Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema
  73. Peripheral Mucosa-homing T Cells In Fibrosis Patients Preferentially Release Th2 Cytokines
  74. Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease
  75. M2 Marker Expression By Alveolar Macrophages Predicts Survival In IPF
  76. Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation
  77. Nachweis einer spezifischen T-Zellantwort gegenüber myko- und propionibakteriellen Antigene bei Sarkoidosepatienten
  78. Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases
  79. Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
  80. CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers
  81. Pulmonary Regulatory T-Cell Counts Correlate with Disease Activity in Patients with Sarcoidosis.
  82. Arginase and NOS2 Are Involved in the Regulation of CCL18 Release.
  83. Influence of CCL18 on Epithelial-to-Mesanchial Transdifferentiation of Epithelial Cells.
  84. CCL18 and IP10 Probe Tumor Cell-Induced Monocyte Differenciation.
  85. Nachweis einer spezifischen T-Zellantwort gegenüber myko- und propionibakteriellen Antigene bei Sarkoidosepatienten
  86. Einfluss von anorganischem Feinstaub auf Epithelzellen und Monozyten
  87. Propionibakterium-Lysat induzierte inflammatorische Lungenveränderungen in Abhängigkeit vom genetischem Hintergrund
  88. Einfluss von CCL18 auf die Epithelial-to-Mesanchial Transdifferentiation (EMT) von Alveolarepithelzellen
  89. CCL18 und IP10 als Marker für Monozytendifferenzierung in Kokultur mit A549 bei Stimulation mit Interferon α, β oder γ
  90. Nekrose und Apoptose humaner Alveolarepithelzellen Typ II nach biaxialer Dehnung
  91. Differences in form stability between human non-tumorous alveolar epithelial cells type 2 and alveolar carcinoma cells under biaxial stretching
  92. Genetik der Sarkoidose: Ein Schlüssel zum Verständnis ihrer Pathogenese
  93. The Hidden Macrophage
  94. Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma
  95. Genetics of Sarcoidosis
  96. Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion
  97. Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts
  98. Phenotyping Sarcoidosis from a Pulmonary Perspective
  99. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
  100. Polymorphismen im ACE- und Angiotensin Rezeptor AT2R1 Gen determinieren den Serum-ACE Spiegel bei Patienten mit Sarkoidose
  101. Expression und Bedeutung des TLR9 auf BAL Zellen von Patienten mit Sarkoidose und EAA
  102. Serum CCL18 Konzentrationen haben einen prognostischen Wert bei der Idiopathischen Lungenfibrose
  103. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
  104. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis
  105. Sarcoidosis-Immunopathogenetic Concepts
  106. IL-10–producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients
  107. Chronische Berylliose
  108. Serotoninergic Receptors on Human Airway Epithelial Cells
  109. Expression und Bedeutung des TLR9 auf BAL Zellen von Patienten mit Sarkoidose und EAA
  110. Genotype-corrected reference values for serum angiotensin-converting enzyme
  111. Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line
  112. Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis
  113. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients
  114. A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18
  115. Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis
  116. Pulmonary TH2 response in Pseudomonas aeruginosa–infected patients with cystic fibrosis
  117. Antigen-Presenting Cells in Sarcoidosis
  118. The P2Y14 Receptor of Airway Epithelial Cells
  119. A role for MCP-1/CCR2 in interstitial lung disease in children
  120. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II
  121. Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough
  122. Monocyte chemoattractant protein MCP-1 gene polymorphism in Sarcoidosis
  123. The Serotoninergic Receptors of Human Dendritic Cells: Identification and Coupling to Cytokine Release
  124. Alveolar macrophages are the main source for tumour necrosis factor‐α in patients with sarcoidosis
  125. Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis
  126. HOPE-Fixation Enables Improved PCR-Based Detection and Differentiation of Mycobacterium tuberculosis Complex in Paraffin-Embedded Tissues
  127. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3
  128. Human alveolar epithelial cells induce nitric oxide synthase‐2 expression in alveolar macrophages
  129. Assessment of Transcriptional Gene Activity in situ by Application of HOPE-fixed, Paraffin-embedded Tissues
  130. Redox states of type 1 ryanodine receptor alter Ca 2+ release channel response to modulators
  131. Formation of Granulomas in the Lungs of Severe Combined Immunodeficient Mice after Infection with Bacillus Calmette-Guerin
  132. Accessory Function and Costimulatory Molecule Expression of Alveolar Macrophages in Patients with Pulmonary Tuberculosis
  133. Pharmacological modulation of the IFNγ-induced accessory function of alveolar macrophages and peripheral blood monocytes
  134. POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSIS
  135. Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA
  136. Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity
  137. Sarcoidosis: historical perspective and immunopathogenesis (part I)
  138. Sarcoidosis: TNF- α Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers
  139. TCR V β Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood
  140. Anti-<I>Borrelia burgdorferi</I> immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report
  141. Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis
  142. Th1/Th2 cell distribution in pulmonary sarcoidosis.
  143. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis.
  144. Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis
  145. Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2
  146. Differentialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker
  147. Value of bronchoalveolar lavage in the differential diagnosis of interstitial lung disease